AstraZeneca's Lokelma To Join Veltassa In Hyperkalemia Sector
Executive Summary
The treatment of hyperkalemia in Europe in patients with chronic kidney disease or chronic heart failure looks set to become more vibrant, with AstraZeneca's Lokelma likely to join Vifor Pharma's Veltassa in the marketplace.
You may also be interested in...
Going Solo Suits Vifor And Its Hopes For Two Blockbusters
Enjoying its independence from Galenica, Switzerland’s third-largest pharmaceutical company believes that Ferinject and Veltassa will help it achieve sales of over CHF2bn by 2020.
AstraZeneca's Pipeline Reaps Rewards Of Return To Science
AstraZeneca rounded off a busy 2017 full of R&D highs, but some huge lows, with a full Phase III pipeline that it says shows how far the company has come since Pascal Soriot took the reins in 2012 and spearheaded a renewed focus on science. But will the company become a victim of its own success?
The 'New' Vifor Pharma: Focused On Specialty Pharma
With a new hyperkalemia therapy nearing EU markets and its injectable iron product showing strong sales growth, Switzerland’s global specialty pharma company Vifor Pharma has been able to upgrade its financial guidance for 2017.